公开(公告)号：WO2021257539A1

公开(公告)日：2021-12-23

申请号：PCT/US2021/037390

申请日：2021-06-15

Applicant: ACADEMIA SINICA

Inventor： WANG, Andrew H.-J. ,  KUO, Wen-Chih ,  LEE, Cheng-Chung ,  YANG, An-Suei

IPC: C07K16/24 ,  A61K39/395 ,  A61K39/00

Abstract: Disclosed herein are anti-IL-1β antibodies capable of binding to human IL-1β and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-IL-1β antibodies and therapeutic and diagnostic uses of such antibodies.

公开(公告)号：WO2021211791A1

公开(公告)日：2021-10-21

申请号：PCT/US2021/027403

申请日：2021-04-15

Applicant: ACADEMIA SINICA ,  WANG, Andrew, H.-J.

Inventor： LEE, Cheng-Chung ,  HSU, Nai-Shu ,  KUO, Wen-Chih

IPC: B82B1/00 ,  C07H21/00 ,  C12Q1/60 ,  C12Q1/68 ,  C40B40/06 ,  G01N33/53

Abstract: The present invention relates to oligonucleotide conjugates and preparation and applications thereof. In particular, the present invention relates to an oligonucleotide conjugated to a biomolecule (e.g. an antibody) and/or an agent of interest (e.g. a drug). In certain embodiments, the oligonucleotide of the present invention is a hybridized complex of a single strand oligonucleotide carrying a biomolecule and a complementary strand oligonucleotide bearing an agent of interest where the hybridized nucleotide segment acts as a linker to link the biomolecule and the agent of interest in one molecule.